MERZ Pharma Canada Inc. is pleased to announce that effective May 19th 2011, XEOMIN(R) (clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins) has been listed with Limited Use Status on the Ontario Drug Benefit formulary (ODB).
